FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study

BACKGROUND: FOLFOX second-line treatment seems to be a validated option for patients with pancreatic cancer (PC) progressing after gemcitabine chemotherapy. However, other therapeutics strategy has developed in first-line therapy, as the FIRGEM phase II study that evaluated gemcitabine alone versus...

詳細記述

保存先:
書誌詳細
主要な著者: Zaanan, Aziz, Trouilloud, Isabelle, Markoutsaki, Theofano, Gauthier, Mélanie, Dupont-Gossart, Anne-Claire, Lecomte, Thierry, Aparicio, Thomas, Artru, Pascal, Thirot-Bidault, Anne, Joubert, Fanny, Fanica, Daniella, Taieb, Julien
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2014
主題:
Research Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4075567/
https://ncbi.nlm.nih.gov/pubmed/24929865
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-441
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料